Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules

PURPOSE: To identify sunitinib alternative schedules (AS) that maintained dose intensity while decreasing adverse events (AEs) in patients with metastatic renal cell cancer (mRCC), and to determine impact of AS on clinical outcomes. PATIENTS AND METHODS: A retrospective review of patients ≥ 18 yr of...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Atkinson, Bradley J., Kalra, Sarathi, Wang, Xuemei, Bathala, Tharakeswara, Corn, Paul, Tannir, Nizar M., Jonasch, Eric
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015627/
https://ncbi.nlm.nih.gov/pubmed/24018239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2013.08.090
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky